Genetic Technologies Ltd - Asset Resilience Ratio
Genetic Technologies Ltd (GTG) has an Asset Resilience Ratio of 0.30% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Genetic Technologies Ltd (GTG) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2024)
This chart shows how Genetic Technologies Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Genetic Technologies Ltd's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Genetic Technologies Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Genetic Technologies Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$18.79K | 0.3% |
| Total Liquid Assets | AU$18.79K | 0.30% |
Asset Resilience Insights
- Limited Liquidity: Genetic Technologies Ltd maintains only 0.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genetic Technologies Ltd Industry Peers by Asset Resilience Ratio
Compare Genetic Technologies Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medpace Holdings Inc
NASDAQ:MEDP |
Diagnostics & Research | 0.00% |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Genetic Technologies Ltd (2002–2024)
The table below shows the annual Asset Resilience Ratio data for Genetic Technologies Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.30% | AU$18.79K ≈ $13.30K |
AU$6.19 Million ≈ $4.38 Million |
+0.19pp |
| 2023-06-30 | 0.12% | AU$17.44K ≈ $12.34K |
AU$14.86 Million ≈ $10.51 Million |
+0.05pp |
| 2022-06-30 | 0.06% | AU$13.26K ≈ $9.38K |
AU$20.80 Million ≈ $14.72 Million |
+0.06pp |
| 2021-06-30 | 0.01% | AU$1.86K ≈ $1.31K |
AU$22.97 Million ≈ $16.25 Million |
0.00pp |
| 2020-06-30 | 0.01% | AU$2.02K ≈ $1.43K |
AU$15.63 Million ≈ $11.06 Million |
-1.62pp |
| 2019-06-30 | 1.64% | AU$53.46K ≈ $37.82K |
AU$3.27 Million ≈ $2.31 Million |
+1.58pp |
| 2018-06-30 | 0.06% | AU$3.50K ≈ $2.48K |
AU$6.17 Million ≈ $4.36 Million |
+0.03pp |
| 2017-06-30 | 0.03% | AU$3.38K ≈ $2.39K |
AU$12.11 Million ≈ $8.57 Million |
0.00pp |
| 2016-06-30 | 0.03% | AU$4.21K ≈ $2.98K |
AU$13.29 Million ≈ $9.40 Million |
+0.01pp |
| 2015-06-30 | 0.02% | AU$3.59K ≈ $2.54K |
AU$20.72 Million ≈ $14.66 Million |
-0.03pp |
| 2014-06-30 | 0.04% | AU$2.95K ≈ $2.09K |
AU$6.73 Million ≈ $4.76 Million |
-2.47pp |
| 2013-06-30 | 2.52% | AU$209.30K ≈ $148.09K |
AU$8.32 Million ≈ $5.89 Million |
+2.41pp |
| 2012-06-30 | 0.11% | AU$17.46K ≈ $12.35K |
AU$16.44 Million ≈ $11.63 Million |
+0.08pp |
| 2011-06-30 | 0.03% | AU$2.65K ≈ $1.87K |
AU$8.92 Million ≈ $6.31 Million |
-0.84pp |
| 2010-06-30 | 0.87% | AU$71.66K ≈ $50.70K |
AU$8.28 Million ≈ $5.86 Million |
+0.86pp |
| 2009-06-30 | 0.00% | AU$200.00 ≈ $141.51 |
AU$22.28 Million ≈ $15.76 Million |
-2.15pp |
| 2008-06-30 | 2.15% | AU$519.12K ≈ $367.31K |
AU$24.15 Million ≈ $17.09 Million |
+1.78pp |
| 2007-06-30 | 0.37% | AU$77.00K ≈ $54.48K |
AU$20.95 Million ≈ $14.82 Million |
+0.07pp |
| 2005-06-30 | 0.30% | AU$88.00K ≈ $62.27K |
AU$29.26 Million ≈ $20.71 Million |
+0.13pp |
| 2004-06-30 | 0.17% | AU$38.44K ≈ $27.20K |
AU$22.39 Million ≈ $15.84 Million |
-0.69pp |
| 2003-06-30 | 0.86% | AU$261.58K ≈ $185.09K |
AU$30.25 Million ≈ $21.40 Million |
+0.65pp |
| 2002-06-30 | 0.21% | AU$70.00K ≈ $49.53K |
AU$33.00 Million ≈ $23.35 Million |
-- |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more